Kura Oncology (KURA) announced receipt of a $30M milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the second of two KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura previously announced receipt of the first $30M milestone triggered by patient dosing in the KOMET-017 trials in October. Kura has received a total of $105M in milestone payments to date and expects to receive up to $315M in additional, near-term milestones under the collaboration.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology (KURA) Q3 Earnings Cheat Sheet
- Kura Oncology’s Promising AML Study: A Potential Game Changer?
- Kura Oncology’s Promising Phase 1 Study on AML Treatment: Key Insights for Investors
- Kura Oncology’s KO-2806 Study: A New Hope for Advanced Solid Tumors?
- Kura Oncology’s Promising GIST Trial: A Potential Game-Changer in Cancer Treatment